Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16847844 | 0.92 | OPRM1 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL21695294 | 0.92 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17801960 | 0.92 | ITGB1 (0.34) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17650869 | 0.92 | PLG (0.36) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17813693 | 0.91 | RAB9A (0.36) | SIRT1OPRM1OPRD1OPRK1FAP | |
| SCHEMBL22698603 | 0.91 | SIRT2 (0.35) | SIRT1OPRM1OPRD1OPRK1FAP | |
| SCHEMBL20830828 | 0.89 | SIRT2 (0.34) | SIRT1OPRM1OPRD1OPRK1FAP | |
| SCHEMBL19683931 | 0.89 | SIRT2 (0.37) | SIRT1FAPSIRT2 | |
| SCHEMBL28953170 | 0.88 | SIRT2 (0.38) | SIRT1FAPSIRT2 | |
| SCHEMBL25413079 | 0.88 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| EP-4185328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3082872-B1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3082875-B1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10017577-B2 | Antibodies and immunoconjugates | GENENTECH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3307780-A1 | ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170002086-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160310611-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | HDAC3 1285/4885HDAC1 1175/4885HDAC2 1414/4885 |
| US-20170002086-A1 | ANTIBODIES AND IMMUNOCONJUGATES | FCGR3B, CD47, FCGR1A | HDAC3 1275/4885HDAC1 3847/4885HDAC2 4027/4885 |
| US-10017577-B2 | Antibodies and immunoconjugates | FCGR3B, CD47, FCGR1A | HDAC3 1275/4885HDAC1 3847/4885HDAC2 4027/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | HDAC3 1734/4885HDAC1 3774/4885HDAC2 1910/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | HDAC3 1285/4885HDAC1 1175/4885HDAC2 1414/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | HDAC3 1091/4885HDAC1 1206/4885HDAC2 679/4885 |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | HDAC3 1734/4885HDAC1 3774/4885HDAC2 1910/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | HDAC3 1734/4885HDAC1 3774/4885HDAC2 1910/4885 |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, VIP | HDAC3 3284/4885HDAC1 3625/4885HDAC2 4165/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | HDAC3 3235/4885HDAC1 3499/4885HDAC2 4029/4885 |
| US-20160310611-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, BCR, LNPEP | HDAC3 3163/4885HDAC1 3486/4885HDAC2 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.